Novartis AG
- Country
- 🇨🇭Switzerland
- Ownership
- Public, Private
- Established
- 1996-01-01
- Employees
- 76K
- Market Cap
- $242.6B
- Introduction
Novartis develops and manufactures innovative drugs. The firm's key areas of drug development include oncology, rare diseases, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States comprising close to one third of total revenue.
Placebo-Controlled Comparison of Two Different Brands of Modified-Release Oral Dosage Forms Regarding Safety and Efficacy in Children With Attention Deficit Hyperactivity Disorder (ADHD) Aged 6 - 14
- Conditions
- ADHD
- First Posted Date
- 2005-11-17
- Last Posted Date
- 2007-12-21
- Lead Sponsor
- Novartis
- Target Recruit Count
- 130
- Registration Number
- NCT00254878
- Locations
- 🇩🇪
Novartis Investigational Site, Freiburg, Germany
A Study to Evaluate the Efficacy of Valsartan/Simvastatin Combinations in Patients With Both Essential Hypertension and Hypercholesterolemia
- Conditions
- Essential HypertensionHypercholesterolemia
- First Posted Date
- 2005-11-16
- Last Posted Date
- 2014-08-19
- Lead Sponsor
- Novartis
- Target Recruit Count
- 871
- Registration Number
- NCT00254475
- Locations
- 🇨🇭
Novartis Pharmaceuticals, Basel, Switzerland
Efficacy and Safety Study of Everolimus Plus Reduced Cyclosporine Versus Mycophenolic Acid Plus Cyclosporine in Kidney Transplant Recipients
- Conditions
- Kidney TransplantationGraft Rejection
- Interventions
- Drug: Mycophenolic Acid (MPA)Drug: Corticosteroids
- First Posted Date
- 2005-11-09
- Last Posted Date
- 2011-05-10
- Lead Sponsor
- Novartis
- Target Recruit Count
- 833
- Registration Number
- NCT00251004
- Locations
- 🇺🇸
Novartis, East Hanover, New Jersey, United States
A Study in Chinese Mild to Moderate Hypertensive Patients Comparing the Efficacy of Co-Diovan With Diovan.
- Conditions
- Hypertension
- First Posted Date
- 2005-11-08
- Last Posted Date
- 2017-08-01
- Lead Sponsor
- Novartis
- Target Recruit Count
- 1171
- Registration Number
- NCT00250562
- Locations
- 🇺🇸
Novartis Pharmaceuticals, East Hanover, New Jersey, United States
A Study to Evaluate the Safety and Efficacy of Clozapine in Patients With Treatment-resistant Schizophrenia
- First Posted Date
- 2005-11-08
- Last Posted Date
- 2016-04-21
- Lead Sponsor
- Novartis
- Target Recruit Count
- 43
- Registration Number
- NCT00250575
- Locations
- 🇯🇵
Novartis Investigational Site, Chiba, Japan
🇯🇵Novartis Investigative Site, Yamanashi, Japan
A Study to Evaluate the Safety and Efficacy of Single Day or Single Dose Famciclovir for the Treatment of Recurrent Herpes Labialis
- Conditions
- Recurrent Herpes Labialis
- First Posted Date
- 2005-11-03
- Last Posted Date
- 2007-12-10
- Lead Sponsor
- Novartis
- Registration Number
- NCT00248144
Comparison Study of Letrozole Alone or Letrozole With Zoledronic Acid in Early Breast Cancer, Neoadjuvant Therapy
- Conditions
- Breast Cancer
- First Posted Date
- 2005-11-02
- Last Posted Date
- 2017-03-01
- Lead Sponsor
- Novartis
- Target Recruit Count
- 190
- Registration Number
- NCT00247650
- Locations
- 🇨🇦
Novartis Investigative Site, Quebec, Canada
A Long Term Study of SPP100 in Patients With Essential Hypertension (Trial is Not Recruiting in the US)
- Conditions
- Hypertension
- First Posted Date
- 2005-10-30
- Last Posted Date
- 2006-07-28
- Lead Sponsor
- Novartis
- Target Recruit Count
- 300
- Registration Number
- NCT00246584
- Locations
- 🇨🇭
Novartis Pharmaceuticals, Basel, Switzerland
TKI258 in Subjects With Refractory or Relapsed Multiple Myeloma
- Conditions
- Multiple Myeloma
- First Posted Date
- 2005-10-25
- Last Posted Date
- 2009-11-23
- Lead Sponsor
- Novartis
- Target Recruit Count
- 64
- Registration Number
- NCT00243763
- Locations
- 🇺🇸
Mayo Clinic - Arizona, Scottsdale, Arizona, United States
🇺🇸H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
🇺🇸Emory University, Atlanta, Georgia, United States
Open-label Study, to Evaluate the Safety and Tolerability of Zoledronic Acid in Patients With Bone Lesions Secondary to Multiple Myeloma.
- Conditions
- Multiple Myeloma
- First Posted Date
- 2005-10-20
- Last Posted Date
- 2015-04-14
- Lead Sponsor
- Novartis
- Registration Number
- NCT00242528